Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sinibolimab + lenvatinib
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Sinibolimab + lenvatinib is a combination therapy regimen being evaluated for the neoadjuvant treatment of locally advanced unresectable differentiated thyroid carcinoma. Sinibolimab is an anti-PD-1 monoclonal antibody that functions as an immune checkpoint inhibitor, enhancing the immune system's ability to detect and destroy tumor cells by blocking the interaction between PD-1 and its ligands. Lenvatinib is an oral multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), RET, KIT, and platelet-derived growth factor receptor alpha (PDGFRα), thereby providing anti-angiogenic and anti-proliferative effects. This combination is currently being studied in a Phase II clinical trial led by Zhejiang University to assess its efficacy in reducing tumor burden and making unresectable tumors eligible for surgical resection (R0/R1 resection).
- Other names
- Sinibolimab plus LenvatinibSinibolimab combined with LenvatinibImmunotherapy combined with Multikinase inhibitors in neoadjuvant treatment
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sinibolimab + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sinibolimab + lenvatinib.